阅读说明：本技术 夏枯草提取物在药物制备中的应用 (Application of selfheal extract in preparation of medicine ) 是由 李定祥 郭碧泽 张�杰 陆家强 李慧民 邱子梁 于 2020-04-22 设计创作，主要内容包括：本发明公开了夏枯草提取物在药物制备中的应用,属于中医药领域。夏枯草提取物由夏枯草果穗经超声浸提、大孔树脂柱梯度洗脱和加热浓缩得到,其用于制备治疗甲状腺癌药物和预防甲状腺癌术后复发药物时均以夏枯草提取物为活性成分,且其总有机酸类成分的重量百分含量不低于20％,总黄酮类成分的重量百分含量不低于10％。本发明通过动物实验证明夏枯草提取物能够有效抑制甲状腺乳头状癌瘤体体积的增大,且与夏枯草提取物有浓度依赖性,可用于治疗甲状腺癌；通过临床试验表明夏枯草提取物具有稳定甲状腺癌患者术后甲状腺功能和其他异常指标,可用于预防甲状腺癌复发,为甲状腺疾病的治疗和预防术后复发提供新的药物途径。(The invention discloses an application of a selfheal extract in medicine preparation, belonging to the field of traditional Chinese medicines. The prunella vulgaris extract is obtained by carrying out ultrasonic extraction, macroporous resin column gradient elution and heating concentration on prunella vulgaris clusters, and when the prunella vulgaris extract is used for preparing a medicine for treating thyroid cancer and a medicine for preventing postoperative recurrence of thyroid cancer, the prunella vulgaris extract is used as an active ingredient, the weight percentage content of the total organic acid ingredients is not less than 20%, and the weight percentage content of the total flavonoid ingredients is not less than 10%. Animal experiments prove that the selfheal extract can effectively inhibit the increase of the volume of papillary thyroid carcinoma tumor bodies, has concentration dependence with the selfheal extract, and can be used for treating thyroid carcinoma; clinical tests show that the prunella vulgaris extract has the effects of stabilizing postoperative thyroid function and other abnormal indexes of thyroid cancer patients, can be used for preventing thyroid cancer recurrence, and provides a new medicine approach for treating thyroid diseases and preventing postoperative recurrence.)

1. Application of Prunellae Spica extract in preparing medicine for treating thyroid cancer is provided.

2. The use as claimed in claim 1, wherein the medicament comprises the Prunellae Spica extract as active ingredient, and has total organic acids not less than 20 wt%, and total flavonoids not less than 10 wt%.

3. The use of claim 2, wherein the medicament further comprises a pharmaceutically acceptable adjuvant or auxiliary ingredient.

4. The use of any one of claims 1 to 3, wherein the dosage form of the medicament comprises but is not limited to oral liquid, extract and injection, wherein the concentration of the selfheal extract oral liquid is 125-500 mg/m L, the administration dose is 10m L times per time, 2 times per day, and the medicament is continuously taken for 3 months.

5. Application of Prunellae Spica extract in preparing medicine for preventing postoperative recurrence of thyroid cancer is provided.

6. The use as claimed in claim 5, wherein the medicament comprises the Prunellae Spica extract as active ingredient, and has total organic acids not less than 20 wt%, and total flavonoids not less than 10 wt%.

7. The use of claim 6, wherein the medicament further comprises pharmaceutically acceptable adjuvants or auxiliary ingredients.

8. The use of any one of claims 5 to 7, wherein the medicament is in the form of an oral liquid of Prunella vulgaris extract, wherein the concentration of Prunella vulgaris extract is 125-500 mg/m L, and the dosage is 10m L/time, 2 times/day, and the administration lasts for 3 months.

9. The use of a prunella vulgaris extract according to any one of claims 1 to 8, wherein said prunella vulgaris extract is prepared by a method comprising:

(1) according to the material-liquid ratio of 1: 5-10 adding water or 80 vol% ethanol aqueous solution into selfheal fruit clusters to carry out ultrasonic extraction for 2h, repeating the ultrasonic extraction for 1-5 times, filtering, and combining extracting solutions to obtain a selfheal crude extract;

(2) carrying out gradient elution on the selfheal crude extract by using a macroporous resin column sequentially through water, 10-30 vol% ethanol water solution and 50-95 vol% ethanol water solution, and collecting eluent eluted through 50-95 vol% ethanol water solution;

(3) and concentrating the obtained eluent at the temperature of 60-70 ℃ until the relative density is 1.05-1.15 to obtain the selfheal extract.

10. The application of the selfheal extract according to claim 8, further comprising the step of processing the selfheal extract into a selfheal extract oral liquid preparation, and specifically, the selfheal extract is kept stand for 12-36 h, filtered, added with auxiliary materials into filtrate, heated and boiled to be dissolved, added with water to the amount of a prescription, mixed uniformly, cooled to 2-10 ℃, refrigerated for 12-36 h, filtered through a microporous filter with the pore diameter of 1 μm, filled with L with the amount of 10.0-10.5 m per unit, and sterilized at 115 ℃ for 15 min.

Technical Field

The invention belongs to the field of traditional Chinese medicines, and relates to application of a selfheal extract in preparation of medicines, in particular to a medicine for treating thyroid cancer and preventing postoperative recurrence of thyroid cancer.

Background

Thyroid Cancer (Thyroid Cancer) is a malignant tumor that originates in the Thyroid follicular epithelium or perifollicular epithelium, and is the most common malignancy of the head and neck. In recent years, the incidence rate of thyroid cancer is rapidly increased in the global scope, and the incidence rate of female thyroid cancer in urban areas of China is 4 th of all malignant tumors of women according to the data display of national tumor registration centers; and thyroid cancer will continue to grow at a rate of 20% per year in our country. The Chinese patent medicine is usually used for combined treatment of thyroid cancer operation, chemotherapy and radiotherapy and is a main treatment means for patients who do not accept operation and radiotherapy and chemotherapy. At present, no specific medicine or postoperative auxiliary treatment means exists for thyroid cancer.

Disclosure of Invention

The invention provides an application of a selfheal extract in preparing a medicine for treating thyroid cancer.

According to some embodiments of the application of the invention, the medicine takes the selfheal extract as an active ingredient, and the weight percentage content of the total organic acid ingredients is not lower than 20%, and the weight percentage content of the total flavonoid ingredients is not lower than 10%.

According to some embodiments of the use of the present invention, the medicament further comprises a pharmaceutically acceptable adjuvant or auxiliary ingredient.

According to some embodiments of the application of the invention, the dosage form of the medicine comprises but is not limited to oral liquid, extract and injection, wherein the concentration of the selfheal extract oral liquid is 125-500 mg/m L, the administration dose is 10m L/time and 2 times/day, and the medicine is continuously taken for 3 months.

The invention also provides application of the selfheal extract in preparing a medicine for preventing postoperative recurrence of thyroid cancer.

According to some embodiments of the application of the invention, the medicine takes the selfheal extract as an active ingredient, and the weight percentage content of the total organic acid ingredients is not lower than 20%, and the weight percentage content of the total flavonoid ingredients is not lower than 10%.

According to some embodiments of the use of the present invention, the medicament further comprises a pharmaceutically acceptable adjuvant or auxiliary ingredient.

According to some embodiments of the application of the present invention, the dosage form of the medicine is prunella vulgaris extract oral liquid, wherein the concentration of the prunella vulgaris extract is 125-500 mg/m L, the administration dosage is 10m L times per time, 2 times per day, and the medicine is continuously taken for 3 months.

According to some embodiments of any of the uses of the present invention, the method for preparing the prunella vulgaris extract comprises:

(1) according to the material-liquid ratio of 1: 5-10 adding water or 80 vol% ethanol aqueous solution into selfheal fruit clusters to carry out ultrasonic extraction for 2h, repeating the ultrasonic extraction for 1-5 times, filtering, and combining extracting solutions to obtain a selfheal crude extract;

(2) carrying out gradient elution on the selfheal crude extract by using a macroporous resin column sequentially through water, 10-30 vol% ethanol water solution and 50-95 vol% ethanol water solution, and collecting eluent eluted through 50-95 vol% ethanol water solution;

(3) and concentrating the obtained eluent at the temperature of 60-70 ℃ until the relative density is 1.05-1.15 to obtain the selfheal extract.

According to some embodiments of any of the applications of the present invention, the ratio of the liquid to the feed in the step (1) is 1: 7, repeating the ultrasonic leaching for three times.

According to some embodiments of any one of the applications of the invention, the method further comprises the step of processing the selfheal extract into a selfheal extract oral liquid preparation, and specifically comprises the steps of standing the selfheal extract for 12-36 hours, filtering, adding auxiliary materials into filtrate, heating and boiling to dissolve the selfheal extract, adding water to the prescription amount, uniformly mixing, cooling to 2-10 ℃, refrigerating for 12-36 hours, filtering through a microporous filter with the pore diameter of 1 μm, filling the mixture with L with the filling amount of 10.0-10.5 m per unit, and sterilizing at 115 ℃ for 15 min.

Compared with the prior art, the invention proves that the selfheal extract can effectively inhibit the increase of the volume of papillary thyroid carcinoma tumor bodies through animal in vivo experiments, has concentration dependence with the selfheal extract, and can be used for treating thyroid carcinoma. Moreover, clinical tests also show that the selfheal extract has the functions of stabilizing the postoperative thyroid function and other abnormal indexes of thyroid cancer patients, can be used for preventing the recurrence of thyroid cancer, and provides a new medicine approach for treating thyroid diseases and preventing the postoperative recurrence.

Drawings

FIG. 1 is a graph of body weight of mice in the papillary thyroid carcinoma model over time during administration in example 2.

FIG. 2 is a graph of tumor volume over time in the papillary thyroid carcinoma model during administration in example 2.

Detailed Description

Embodiments of the present invention will be described in detail below with reference to the drawings and examples, but those skilled in the art will understand that the following examples are only illustrative of the present invention and should not be construed as limiting the scope of the present invention. The examples, in which specific conditions are not specified, were conducted under conventional conditions or conditions recommended by the manufacturer. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products commercially available.